Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02660944 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 2 study, sponsored by Resolve Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT02660944 is a Phase 2 study that has completed, run by Resolve Therapeutics. The registered enrollment target is 64 participants.
The verdict
NCT02660944, a Phase 2 study, has completed, sponsored by Resolve Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This study evaluates the impact of 13 bi-weekly intravenous infusions of RSLV-132 on the cutaneous manifestations in subjects with systemic lupus erythematosus.
Interventions
- DRUG Placebo
- DRUG RSLV-132
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2016-01-03 |
| Est. Completion | 2020-08-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02660944
The ClinicalTrials.gov registry entry for NCT02660944 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Resolve Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02660944 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02660944 about?
NCT02660944 is a clinical study titled "A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)". This study evaluates the impact of 13 bi-weekly intravenous infusions of RSLV-132 on the cutaneous manifestations in subjects with systemic lupus erythematosus.
What is the current status of trial NCT02660944?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2016-01-03. Estimated completion is 2020-08-10.
What interventions are being tested in trial NCT02660944?
The interventions under investigation include: Placebo (DRUG), RSLV-132 (DRUG).
Who is sponsoring clinical trial NCT02660944?
This trial is sponsored by Resolve Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.